NO873031L - Ionebytterharpiks. - Google Patents

Ionebytterharpiks.

Info

Publication number: NO873031L
Authority: NO; Norway
Prior art keywords: resin; drug; particles; approx; impregnating agent
Prior art date: 1986-07-30

Application number

NO873031A

Other languages

English (en)

Norwegian (no)

Other versions

NO873031D0 (no

Inventor

San-Laung Chow

Yegnaswami Raghunathan

Original Assignee

Pennwalt Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-07-30

Filing date

1987-07-20

Publication date

1988-02-01

1987-07-20 Application filed by Pennwalt Corp filed Critical Pennwalt Corp

1987-07-20 Publication of NO873031D0 publication Critical patent/NO873031D0/no

1988-02-01 Publication of NO873031L publication Critical patent/NO873031L/no

Links

NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 title claims description 9
239000003456 ion exchange resin Substances 0.000 title description 5
229920003303 ion-exchange polymer Polymers 0.000 title description 5
239000011347 resin Substances 0.000 claims abstract description 48
229920005989 resin Polymers 0.000 claims abstract description 48
239000002245 particle Substances 0.000 claims abstract description 35
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 10
239000000600 sorbitol Substances 0.000 claims abstract description 10
235000010356 sorbitol Nutrition 0.000 claims abstract description 10
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 6
239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 6
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 6
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 6
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 6
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 6
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 6
239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 5
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 4
239000003795 chemical substances by application Substances 0.000 claims description 27
238000000576 coating method Methods 0.000 claims description 26
239000011248 coating agent Substances 0.000 claims description 24
239000003814 drug Substances 0.000 claims description 24
238000002360 preparation method Methods 0.000 claims description 11
230000004888 barrier function Effects 0.000 claims description 7
238000009792 diffusion process Methods 0.000 claims description 7
239000003729 cation exchange resin Substances 0.000 claims description 6
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 4
239000000825 pharmaceutical preparation Substances 0.000 claims description 3
IIGSLJHOCDIPJX-HFYYSOHNSA-N OCCCC(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO Chemical compound OCCCC(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO IIGSLJHOCDIPJX-HFYYSOHNSA-N 0.000 claims description 2
-1 hydroxypropyl sorbitol Chemical compound 0.000 abstract description 2
150000001875 compounds Chemical class 0.000 abstract 1
229940079593 drug Drugs 0.000 description 22
DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 16
DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 16
229960000395 phenylpropanolamine Drugs 0.000 description 16
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
238000004090 dissolution Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
229920001429 chelating resin Polymers 0.000 description 5
238000000034 method Methods 0.000 description 5
239000001856 Ethyl cellulose Substances 0.000 description 4
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
229920001249 ethyl cellulose Polymers 0.000 description 4
235000019325 ethyl cellulose Nutrition 0.000 description 4
239000012530 fluid Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000000052 comparative effect Effects 0.000 description 3
239000008367 deionised water Substances 0.000 description 3
229910021641 deionized water Inorganic materials 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
230000009918 complex formation Effects 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
238000005470 impregnation Methods 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
231100000563 toxic property Toxicity 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
QWFMDSOYEQHWMF-UHFFFAOYSA-N 2,3-bis(ethenyl)benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC(C=C)=C1C=C QWFMDSOYEQHWMF-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
229960001985 dextromethorphan Drugs 0.000 description 1
XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
239000012738 dissolution medium Substances 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
229960005426 doxepin Drugs 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229960002179 ephedrine Drugs 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
229960002474 hydralazine Drugs 0.000 description 1
LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
229960000240 hydrocodone Drugs 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000012528 membrane Substances 0.000 description 1
LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
229960002657 orciprenaline Drugs 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
229960003908 pseudoephedrine Drugs 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Processes Of Treating Macromolecular Substances (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Compositions Of Macromolecular Compounds (AREA)
Laminated Bodies (AREA)
Paints Or Removers (AREA)
Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Physical Or Chemical Processes And Apparatus (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Treatment Of Water By Ion Exchange (AREA)
Pyridine Compounds (AREA)

NO873031A 1986-07-30 1987-07-20 Ionebytterharpiks. NO873031L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US89216986A	1986-07-30	1986-07-30

Publications (2)

Publication Number	Publication Date
NO873031D0 NO873031D0 (no)	1987-07-20
NO873031L true NO873031L (no)	1988-02-01

Family

ID=25399487

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO873031A NO873031L (no)	1986-07-30	1987-07-20	Ionebytterharpiks.

Country Status (13)

Country	Link
EP (1)	EP0254811B1 (de)
JP (1)	JP2670777B2 (de)
KR (1)	KR960012067B1 (de)
AT (1)	ATE93164T1 (de)
AU (1)	AU582302B2 (de)
CA (1)	CA1283998C (de)
DE (1)	DE3787060T2 (de)
DK (1)	DK394787A (de)
FI (1)	FI872582A (de)
IE (1)	IE62100B1 (de)
IL (1)	IL82223A0 (de)
NO (1)	NO873031L (de)
NZ (1)	NZ219816A (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4996047A (en) *	1988-11-02	1991-02-26	Richardson-Vicks, Inc.	Sustained release drug-resin complexes
US5186930A (en) *	1988-11-14	1993-02-16	Schering Corporation	Sustained release oral suspensions
US4999189A (en) *	1988-11-14	1991-03-12	Schering Corporation	Sustained release oral suspensions
US5149523A (en) *	1989-06-20	1992-09-22	Aktiebolaget Hassle	Polystyrenesulfonate-drug complex and solid dosage forms thereof
SE9003903D0 (sv) *	1990-12-07	1990-12-07	Astra Ab	New pharmaceutical formulations
US5275820A (en) *	1990-12-27	1994-01-04	Allergan, Inc.	Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
US5296228A (en) *	1992-03-13	1994-03-22	Allergan, Inc.	Compositions for controlled delivery of pharmaceutical compounds
JP3213712B2 (ja) *	1992-08-04	2001-10-02	全日本空輸株式会社	コンテナ自動移載装置および移載方法
JPH06305518A (ja) *	1993-04-23	1994-11-01	Kajima Corp	収納設備
WO1999020285A1 (fr) *	1997-10-16	1999-04-29	Sanwa Kagaku Kenkyusho Co., Ltd.	Preparations de gels contenant un polystyrenesulfonate
US6280717B1 (en)	1998-07-31	2001-08-28	Nikken Chemicals Co., Ltd.	Cation exchange resin preparation
JP3866179B2 (ja) *	2002-10-09	2007-01-10	ダイセル化学工業株式会社	光学異性体分離用充填剤の製造方法
CA2509429A1 (en)	2002-11-26	2004-06-10	University Of Maryland, Baltimore	Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
EP1667658A2 (de)	2003-09-03	2006-06-14	Mallinckrodt Inc.	Granulatförmiges präparat mit verzögerter freisetzung und seine herstellung
EP2361611A3 (de) *	2005-06-09	2011-10-12	Upm Pharmaceuticals, Inc.	Wässriges, anhaltend freisetzendes Arzneimittelabgabesystem für stark wasserlösliche, elektrolytische Arzneimittel
US8343546B2 (en) *	2005-09-13	2013-01-01	Coating Place, Inc.	Ion exchange resin treated to control swelling
WO2007038801A2 (en) *	2005-09-30	2007-04-05	Ilypsa, Inc.	Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB982150A (en) *	1961-09-29	1965-02-03	Glaxo Group Ltd	Therapeutic resin complexes
US3594470A (en) *	1968-02-19	1971-07-20	Abbott Lab	Chewable tablets including coated particles of pseudoephedrine-weak cation exchange resin
US4221778A (en) *	1979-01-08	1980-09-09	Pennwalt Corporation	Prolonged release pharmaceutical preparations
CA1236023A (en) *	1984-07-18	1988-05-03	Yegnaswami Raghunathan	Controlled release pharmaceutical preparations
NZ219925A (en) *	1986-07-30	1989-06-28	Pennwalt Corp	Polymer-treated sulphonic acid cationic exchange resin particles

1987
- 1987-03-26 IE IE78987A patent/IE62100B1/en not_active IP Right Cessation
- 1987-03-30 NZ NZ219816A patent/NZ219816A/xx unknown
- 1987-04-02 AU AU70989/87A patent/AU582302B2/en not_active Expired - Fee Related
- 1987-04-14 DE DE87105503T patent/DE3787060T2/de not_active Expired - Fee Related
- 1987-04-14 EP EP87105503A patent/EP0254811B1/de not_active Expired - Lifetime
- 1987-04-14 AT AT87105503T patent/ATE93164T1/de not_active IP Right Cessation
- 1987-04-16 IL IL82223A patent/IL82223A0/xx unknown
- 1987-04-24 CA CA000535550A patent/CA1283998C/en not_active Expired - Fee Related
- 1987-06-09 FI FI872582A patent/FI872582A/fi not_active IP Right Cessation
- 1987-07-20 NO NO873031A patent/NO873031L/no unknown
- 1987-07-28 JP JP62186781A patent/JP2670777B2/ja not_active Expired - Fee Related
- 1987-07-29 DK DK394787A patent/DK394787A/da not_active Application Discontinuation
- 1987-07-30 KR KR1019870008332A patent/KR960012067B1/ko not_active IP Right Cessation

Also Published As

Publication number	Publication date
IL82223A0 (en)	1987-10-30
NO873031D0 (no)	1987-07-20
DK394787D0 (da)	1987-07-29
KR960012067B1 (ko)	1996-09-12
DE3787060D1 (de)	1993-09-23
EP0254811A2 (de)	1988-02-03
NZ219816A (en)	1989-01-06
AU582302B2 (en)	1989-03-16
DK394787A (da)	1988-05-02
JPS6335527A (ja)	1988-02-16
EP0254811B1 (de)	1993-08-18
CA1283998C (en)	1991-05-07
DE3787060T2 (de)	1993-12-02
JP2670777B2 (ja)	1997-10-29
AU7098987A (en)	1988-02-04
KR880001302A (ko)	1988-04-22
ATE93164T1 (de)	1993-09-15
FI872582A0 (fi)	1987-06-09
IE870789L (en)	1988-01-30
IE62100B1 (en)	1994-12-14
FI872582A (fi)	1988-01-31
EP0254811A3 (en)	1989-04-05

Publication	Publication Date	Title
US4859461A (en)	1989-08-22	Coatable ion exchange resins
US4847077A (en)	1989-07-11	Controlled release pharmaceutical preparations
NO873031L (no)	1988-02-01	Ionebytterharpiks.
US4959219A (en)	1990-09-25	Coating barriers comprising ethyl cellulose
CA1236023A (en)	1988-05-03	Controlled release pharmaceutical preparations
DK175659B1 (da)	2005-01-10	Farmaceutisk sammensætning på enhedsdosisform til peroral administration
US4859462A (en)	1989-08-22	Polymer-treated ion exchange resins
DK160601B (da)	1991-04-02	Farmaceutisk harpiksholdigt, sustained release praeparat med kontrolleret afgivelse af et farmaceutisk acceptabelt syreadditionssalt af dextromethorphan samt fremgangsmaade til fremstilling deraf
US4518588A (en)	1985-05-21	Process for the preparation of an inclusion complex of N-(1--phenylethyl)-3,3-diphenylpropylamine and the hydrochloride thereof respectively with cyclodextrin
CA1283497C (en)	1991-04-23	Polymer-treated ion exchange resins
AU663695B2 (en)	1995-10-19	Polyamine drug-resin complexes
JPS609697B2 (ja)	1985-03-12	製剤
US4369175A (en)	1983-01-18	Process for the manufacture of prolonged action vincamine preparations, the vincamine preparations so obtained, and medicaments containing them
KR0135736B1 (ko)	1998-04-23	안정한 오메프라졸 레진염
JPH01313431A (ja)	1989-12-18	ジルチアゼム・マイクロビーズ、その製法および徐放性医薬組成物
KR20200106503A (ko)	2020-09-14	가교결합된 이온 교환 수지를 함유하는 약학적 조성물
Chattaraj et al.	1990	Effect of formulation variables on the preparation and in vitro-in vivo evaluation of cimetidine release from ethyl cellulose micropellets
CN114869845A (zh)	2022-08-09	一种磷酸奥司他韦缓释混悬剂及其制备方法
KR20200117999A (ko)	2020-10-14	수지 입자를 함유하는 약학적 조성물
JPH0569837B2 (de)	1993-10-01
GB2078758A (en)	1982-01-13	Prolonged Action Vincamine Preparations
JPS5815173B2 (ja)	1983-03-24	マイクロカプセルの調整方法